MedtronicBSP:MDTC34 +2.96%67 FCF Margin % is 21.26% as of Apr. 2026, which is 32% above its 10-year median of 16.15. GuruFocus rates BSP:MDTC34 with a GF Score™ of 67/100 and a GF Value™ of R$260.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Medtronic ranks better than 84.42% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medtronic's Free Cash Flow for the
three
months ended in Apr. 2026 was R$10,496 Mil. Medtronic's Revenue for the
three
months ended in Apr. 2026 was R$49,367 Mil. Therefore, Medtronic's FCF Margin % for the quarter that ended in Apr. 2026 was 21.26%.
The historical rank and industry rank for Medtronic's FCF Margin % or its related term are showing as below:
BSP:MDTC34'
s FCF Margin % Range Over the Past 10 Years
Min: 12.07 Med: 16.15 Max: 20.82
Current: 14.73
During the past 13 years, the highest FCF Margin % of Medtronic was 20.82%. The lowest was 12.07%. And the median was 16.15%.
BSP:MDTC34's FCF Margin % is ranked better than 84.42% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs BSP:MDTC34: 14.73
Medtronic FCF Margin % Related Terms
Medtronic FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medtronic's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:MDTC34 vs SYK, BSX, EW: FCF Margin % Comparison
For the Medical Devices subindustry, Medtronic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medtronic's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtronic (BSP:MDTC34) has a FCF Margin % of 21.26% as of Apr. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medtronic and its competitors. This is 32% above median its historical median of 16.15. Over the past decade, Medtronic's FCF Margin % has ranged from 12.07 to 20.82. According to the industry distribution chart, Medtronic ranks #127 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 15.6%.
Is Medtronic's FCF Margin % too high?
Medtronic's current FCF Margin % of 21.26% is 32% above median its 10-year median of 16.15. Over the past 10 years, this metric has ranged from a low of 12.07 to a high of 20.82. Based on the distribution chart, Medtronic ranks #127 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medtronic has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's FCF Margin % compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #127 out of 815 companies for FCF Margin %. This places Medtronic in the top 16% of its industry — outperforming the majority of peers. Historically, Medtronic's own FCF Margin % has ranged from 12.07 to 20.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medtronic and its competitors. Medtronic's current FCF Margin % is 21.26%, which is 32% above median its own 10-year median of 16.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$260.36, compared to a current price of R$209.95 — trading 19.4% below its estimated fair value. The current FCF Margin % is 21.26%, which is 32% above median its 10-year median of 16.15. Medtronic's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current FCF Margin % is 21.26% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$209.95 is trading 19.4% below its estimated GF Value™ of R$260.36.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for BSP:MDTC34:
FCF Margin %: 21.26% (32% above median its 10-year median of 16.15)
GF Value™: R$260.36 vs. price of R$209.95 (19.4% below fair value)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
67GF Score
Get the complete analysis for BSP:MDTC34
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
